

December 20, 2023

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Trastuzumab deruxtecan (Enhertu)

We refer to our earlier communication dated May 3, 2023 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Enhertu in January 2024 in India.

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

We request you to kindly take the above on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary